Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomised, Controlled, Double Masked, Multiple Dose Study of the Safety, Tolerability and Efficacy of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa

NCT06628947 is registered in ClinicalTrials.gov with Kiora Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06628947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06628947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomised, Controlled, Double Masked, Multiple Dose Study of the Safety, Tolerability and Efficacy of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
Lead sponsor
Kiora Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
August 29, 2025
Completion date
August 31, 2027
Enrollment
36 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

retinitis pigmentosa